Literature DB >> 10657016

Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus.

J W van Sandick1, J P Baak, J J van Lanschot, W Polkowski, F J ten Kate, H Obertop, G J Offerhaus.   

Abstract

Decision models for surveillance of Barrett's oesophagus (BO) are governed by the grade of dysplasia on endoscopic biopsy, but subjective grading is prone to observer variation. Computerized morphometry and immunoquantitation can objectively discriminate between different grades of dysplasia in oesophagectomy specimens with BO. The present study evaluated the feasibility of such quantitative analysis on surveillance biopsies of BO. Biopsy criteria for quantitative analysis were defined, excluding 101 (21%) of 472 archival BO surveillance biopsies. In the remaining haematoxylin and eosin (H&E) sections, 105 areas that distinctively displayed no dysplasia (ND), low-grade dysplasia (LGD) or high-grade dysplasia (HGD) were demarcated. Agreement on double-blind examination by two experienced pathologists was reached in 66 areas (63%; kappa: 0.44). For 21 ND/LGD and 11 LGD/HGD disagreement areas, corresponding sections for p53 and Ki67 immunohistochemistry were available. The best combination of two discriminating features was stratification index (SI) with p53 area % for ND versus LGD (89% correct classification), and SI with Ki67 area % for LGD versus HGD (91% correct classification). Fifteen of the 21 ND/LGD disagreement areas could be classified uniquely as either ND or LGD by SI and p53, and eight of the 11 LGD/HGD disagreement areas as either LGD or HGD by SI and Ki67. Correlation coefficients for repeated measurements of SI, Ki67, and p53 by the same observer were 0.94, 0.92, and 0.86, and by two independent observers 0.86, 0.93, and 0.92, respectively. Computerized quantitative pathology on BO surveillance biopsies is feasible provided that well-defined biopsy criteria are used. Using a combination of features associated with cellular differentiation and proliferation, such as SI, p53, and Ki67, quantitative pathological analysis assists in reducing diagnostic variability in the grading of dysplasia during surveillance of BO. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10657016     DOI: 10.1002/(SICI)1096-9896(200002)190:2<177::AID-PATH508>3.0.CO;2-X

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  15 in total

1.  Routine morphometrical analysis can improve reproducibility of dysplasia grade in Barrett's oesophagus surveillance biopsies.

Authors:  J P A Baak; F J W ten Kate; G J A Offerhaus; J J van Lanschot; G A Meijer
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

Review 2.  Report of an Amsterdam working group on Barrett esophagus.

Authors:  G J A Offerhaus; P Correa; S van Eeden; K Geboes; P Drillenburg; M Vieth; M L van Velthuysen; H Watanabe; P Sipponen; F J W ten Kate; F T Bosman; A Bosma; A Ristimaki; H van Dekken; R Riddell; G N J Tytgat
Journal:  Virchows Arch       Date:  2003-09-27       Impact factor: 4.064

3.  Advances in cancer tissue microarray technology: Towards improved understanding and diagnostics.

Authors:  Wenjin Chen; David J Foran
Journal:  Anal Chim Acta       Date:  2006-01-23       Impact factor: 6.558

Review 4.  Screening and surveillance of Barrett's esophagus.

Authors:  Jeff Michalak; Ajay Bansal; Prateek Sharma
Journal:  Curr Gastroenterol Rep       Date:  2009-06

Review 5.  Diagnosis and grading of dysplasia in Barrett's oesophagus.

Authors:  R D Odze
Journal:  J Clin Pathol       Date:  2006-10       Impact factor: 3.411

6.  Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables.

Authors:  P S Rabinovitch; G Longton; P L Blount; D S Levine; B J Reid
Journal:  Am J Gastroenterol       Date:  2001-11       Impact factor: 10.864

7.  Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.

Authors:  B J Reid; L J Prevo; P C Galipeau; C A Sanchez; G Longton; D S Levine; P L Blount; P S Rabinovitch
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

8.  Dysplasia discrimination in intestinal-type neoplasia of the esophagus and colon via digital image analysis.

Authors:  David R Martin; David R Braxton; Alton B Farris
Journal:  Virchows Arch       Date:  2016-08-05       Impact factor: 4.064

Review 9.  [Subjective grading of Barrett's neoplasia by pathologists: correlation with objective histomorphometric variables].

Authors:  E Sabo; G Klorin; E Montgomery; K C Drumea; O Ben-Izhak; J Lachter; M Vieth
Journal:  Pathologe       Date:  2013-03       Impact factor: 1.011

10.  Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study.

Authors:  Eric D Hsi; Sin-Ho Jung; Raymond Lai; Jeffrey L Johnson; James R Cook; Dan Jones; Sven Devos; Bruce D Cheson; Lloyd E Damon; Jonathan Said
Journal:  Leuk Lymphoma       Date:  2008-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.